With recent US Food and Drug Administration (FDA) approvals for ALK-, EGFR-, and ROS1-targeted medications and PD-1/PD-L1–directed immunotherapy, the options available for the treatment of advanced or metastatic NSCLC have expanded. This evidence concerns the gene EGFR and non-small cell lung carcinoma.